envafolimab
mAbexperimental
Clinical trial activity
93 trials · 43 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
84
Phase 3
5
Phase 4
0
Earliest trial started Jan 13, 2017 (NCT02827968)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 3
- Biomarkers, Pharmacological · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2/Phase 3
- Drugs, Investigational · Phase 2
- Drug Therapy · Phase 2
- Endometrial Neoplasms · Phase 2
- Endostatins · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Fibrosarcoma · Phase 2
- Gallbladder Neoplasms · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Head and Neck Neoplasms · Phase 2
- Healthy Volunteers · Phase 1
- Hepatitis B, Chronic · Phase 2
- HIV Infections · Phase 2
- Immune Checkpoint Inhibitors · Phase 2
- Immunotherapy · Phase 2
- Induction Chemotherapy · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 2
- Melanoma · Phase 2
- Mutation · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoadjuvant Therapy · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neoplasms, Multiple Primary · Phase 2
- Osteosarcoma · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pharmacological and Toxicological Phenomena · Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Radiotherapy · Phase 2
- Rectal Neoplasms · Phase 3
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 3
- Thymoma · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Programmed cell death 1 ligand 1BINDING AGENT
Programmed cell death 1 ligand 1 binding agent
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298006 ↗
Also known as
- kn035
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07288034 | Phase 2 | Sep 21, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07243626 | Phase 2 | Dec 30, 2025 | Zhejiang University |
| NCT07256223 | Phase 2 | Dec 1, 2025 | Fudan University |
| NCT07159191 | Phase 2 | Sep 1, 2025 | Chinese Academy of Medical Sciences |
| NCT07142863 | Phase 2 | Aug 25, 2025 | Jiao Tong University |
| NCT06772233 | Phase 2 | Jul 30, 2025 | Peking University |
| NCT07003815 | Phase 2 | Jun 30, 2025 | Huazhong University of Science and Technology |
| NCT06942234 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2025 | Alphamab Co., Ltd. |
| NCT06959693 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2025 | Sun Yat-Sen University |
| NCT07000305 | Phase 2 | May 20, 2025 | Huazhong University of Science and Technology |
| NCT06868732 | Phase 1 | Mar 12, 2025 | Alphamab Co., Ltd., Sun Yat-Sen University |
| NCT06775483 | Phase 2 | Jan 17, 2025 | Alphamab Co., Ltd., Sun Yat-Sen University |
| NCT06692491 | Phase 2 | Jan 1, 2025 | Peking University |
| NCT06876844 | Phase 2 | Dec 30, 2024 | Jiao Tong University |
| NCT07260305 | Phase 1 | Nov 27, 2024 | Kangabio |
| NCT06656559 | Phase 2 | Oct 31, 2024 | Tianjin Medical University |
| NCT06698965 | Phase 2 | Oct 13, 2024 | Jiao Tong University, Simcere Pharmaceutical Co., Ltd |
| NCT06618391 | Phase 2 | Oct 8, 2024 | Henan Medical University |
| NCT06663007 | Phase 1/Phase 2 (Phase 2) | Sep 24, 2024 | Tianjin Medical University |
| NCT06470971 | Phase 2 | Jul 31, 2024 | Ohio State University |
Showing 20 of 93 trials
Page 1 / 5
Organizations
Research & Development (43)
43 organizations
Page 1 / 3